Literature DB >> 10767596

A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides.

I Jääskeläinen1, S Peltola, P Honkakoski, J Mönkkönen, A Urtti.   

Abstract

Anti-sense oligonucleotides are potential therapeutic agents that are used to block protein expression from mRNA. To assess the essential properties for an efficient cellular delivery system of phosphorothioate oligonucleotides (PS-ODNs), different cationic carriers were compared. The carriers were complexed with oligonucleotides at various +/- charge ratios in MES-Hepes buffer. Cationic polymers, polylysines (PLL, mean MWs 4000, 20000, 200000 kDa), polyethyleneimines (PEI, mean MWs 25 and 800 kDa) and fractured sixth-generation polyamidoamine dendrimer (PAMAM) were tested for ODN delivery into a D 407 cell line (human retinal pigment epithelial cells) with stably transfected luciferase gene. Anti-sense ODN was directed against the luciferase gene, and the anti-sense effect was determined using a luminometric method. Lipid-based vehicles included DOTAP, DOTAP/DOPE (1/1 by mol), DOTAP/Chol (1/1 by mol), DOTAP/DOPE/Chol (2/1/1 by mol), DOGS and Cytofectin GS/DOPE (2/1 by mol). Additionally a membrane-active peptide JTS-1 (NH(2) -GLFEALLELLESLWELLLEA-COOH) was added to the complexes containing DOTAP, PEI or PLL. In D 407 and CV-1 cells, the anti-sense effect was seen only with lipid-based carriers with a membrane-active component (DOPE or JTS-1). The polymeric systems were ineffective. The effect of the complexation medium was further studied on CV-1 cells. Complexes were prepared in either water, MES-Hepes buffer or cell growth medium (DMEM). Complexes prepared in water were generally most effective and the greater activity is probably due to the smaller complex size. Complex sizes differed greatly in buffer and DMEM, especially in the case of DOPE containing complexes. In conclusion, lipid carrier with a membrane active component and small complex size are required for an efficient cellular delivery of phosphorothioate oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767596     DOI: 10.1016/s0928-0987(00)00068-3

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  11 in total

1.  Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model.

Authors:  Leena Pitkänen; Jukka Pelkonen; Marika Ruponen; Seppo Rönkkö; Arto Urtti
Journal:  AAPS J       Date:  2004-10-07       Impact factor: 4.009

2.  Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy.

Authors:  Ana L Gomes dos Santos; Amélie Bochot; Nicolas Tsapis; Franck Artzner; Riad Antoine Bejjani; Brigitte Thillaye-Goldenberg; Yvonne de Kozak; Elias Fattal; Francine Behar-Cohen
Journal:  Pharm Res       Date:  2006-04-06       Impact factor: 4.200

3.  Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides.

Authors:  Li Kim Lee; Charity L Williams; David Devore; Charles M Roth
Journal:  Biomacromolecules       Date:  2006-05       Impact factor: 6.988

4.  Novel pH-sensitive cationic lipids with linear ortho ester linkers for gene delivery.

Authors:  Haigang Chen; Huizhen Zhang; Der Thor; Roshanak Rahimian; Xin Guo
Journal:  Eur J Med Chem       Date:  2012-03-16       Impact factor: 6.514

5.  Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers.

Authors:  Leena Pitkänen; Marika Ruponen; Jenni Nieminen; Arto Urtti
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

Review 6.  Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor κB transcription factor decoy oligodeoxynucleotides.

Authors:  Leila Farahmand; Behrad Darvishi; Keivan Majidzadeh-A
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics.

Authors:  R K Khar; G K Jain; M H Warsi; N Mallick; S Akhter; S A Pathan; F J Ahmad
Journal:  Indian J Pharm Sci       Date:  2010-11       Impact factor: 0.975

Review 8.  Respirable antisense oligonucleotides: a new drug class for respiratory disease.

Authors:  M Tanaka; J W Nyce
Journal:  Respir Res       Date:  2000-12-18

9.  Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.

Authors:  Pedro M D Moreno; Ana P Pêgo
Journal:  Front Chem       Date:  2014-10-14       Impact factor: 5.221

10.  Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.

Authors:  Emanuela Gentile; Taro Oba; Jing Lin; Ruping Shao; Feng Meng; Xiaobo Cao; Heather Y Lin; Majidi Mourad; Apar Pataer; Veerabhadran Baladandayuthapani; Dong Cai; Jack A Roth; Lin Ji
Journal:  Oncotarget       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.